CNS-Focused Pharmaceutical Company Lundbeck Extends Enterprise Contract with Medidata Solutions

Denmark-based Research Intensive Drug Company Extends Multiyear Agreement for Use of Medidata Rave in its Worldwide Clinical Trials

NEW YORK--(BUSINESS WIRE)-- Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that Denmark-based H. Lundbeck A/S has extended its agreement to use the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) platform for another multi-year period, building on the success of the relationship in the initial three-year contract.

Lundbeck, one of Denmark’s most research-intensive enterprises, focuses on therapies for central nervous system (CNS) disorders, including depression and anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson’s diseases. Headquartered in Copenhagen with 5,900 employees around the world, Lundbeck selected Rave initially in 2007 as an enterprise-wide EDC system based on its ability to handle large, complex, global studies and its collaboration-enabling data collection, management and reporting capabilities. Since then, Lundbeck has used Medidata Rave in all Phase II-III clinical studies, covering a broad range of patients, countries and sites. The new multi-year contract calls for Rave use in all Lundbeck’s upcoming Phases II and III trials.

“Lundbeck is a great example of a sponsor leveraging Rave as the hub of its clinical development process, not only across the U.S. and Europe, but on a global scale,” said Tarek Sherif, Chairman and CEO, Medidata Solutions. “We have developed a strong partnership with Lundbeck over the past two years and are proud to continue to play a key role in supporting the company’s strong pipeline of CNS therapies.”

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded by Hans Lundbeck in 1915 in Copenhagen, Denmark, and today employs 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2009, the company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com.

About Medidata Solutions Worldwide

Medidata Solutions (www.mdsol.com) is a leading global provider of SaaS-based clinical development solutions that enhance the efficiency of customers’ clinical trials. For over 10 years, Medidata has consistently brought next-generation innovation to the life science industry to lower the total cost of clinical development through informed trial planning and management, optimized clinical processes and platform interoperability. Medidata’s advanced solutions address key functions throughout the clinical development process including protocol development (Medidata Designer®), trial planning and management (Medidata Grants Manager®, Medidata CRO Contractor®), user and learning management (iMedidata™), randomization and trial supply management (Medidata Balance™), monitoring (Medidata Rave Monitor, Medidata Rave Targeted SDV), Serious Adverse Events capture (Medidata Rave Safety Gateway) and clinical data capture, management and reporting (Medidata Rave®). Our diverse customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.



CONTACT:

Lois Paul & Partners
Susan McCarron, 781-782-5767
[email protected]

KEYWORDS:   United States  Europe  Asia Pacific  North America  Canada  China  New York  Japan

INDUSTRY KEYWORDS:   Technology  Data Management  Software  Health  Biotechnology  Medical Devices  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.